Skip to Main Content
Yair Lotan, M.D.

Yair Lotan, M.D.

Titles and Appointments

Professor

Endowed Title
Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D.
School
Medical School
Department
Urology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Yair Lotan, M.D., is a Professor of Urology, Chief of Urologic Oncology, and holder of the Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D. at UT Southwestern Medical Center. He is also Vice Chair for Clinical Affairs and director of the Clinical Research Office in the department of urology and the Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System.

    He was class valedictorian in high school and graduated with high honors from the University of Texas at Austin and Baylor College of Medicine in Houston. He trained in general surgery and urology at UT Southwestern and joined the faculty in 2003.

    A board-certified urologist, Dr. Lotan treats patients with bladderprostatekidney, ureteral, and testicular cancer. He also handles general urologic conditions, such as kidney stones and vasectomies.

    He is known nationally for his research on urine markers and molecular markers, which will help determine which patients are at higher risk for recurrent cancer. He is also involved in health economics research, which evaluates the cost-effectiveness of surgery and cancer prevention.   He has participated in multiple collaborative studies involving early detection of bladder cancer.  He is also a co-investigator on several NIH funded trials evaluating urine based tumor markers. Dr. Lotan is the primary investigator on several investigator-initiated studies evaluating the role of urine and tissue markers in management of bladder cancer.  He is a member of several guidelines panels for evaluation of hematuria and management of muscle invasive bladder cancer.  He has published over 600 peer reviewed papers and multiple reviews and book chapters.    Dr. Lotan is the co-chair of the Harold C. Simmons Comprehensive Cancer Center disease oriented team for urologic cancers. He is also a member of UT Southwestern’s Clinical Research Planning Group and the Tissue Bank Steering Committee and Cancer Committee.

    He is a frequent guest speaker at medical conferences around the world and belongs to numerous professional organizations, including the American Urological Association, the Society of Urologic Oncology, and the Bladder Cancer Advocacy Network.

    He has published over 600 peer-reviewed research articles and several book chapters on urologic care and procedures, and he serves as editorial reviewer for medical periodicals such as the Journal of UrologyEuropean UrologyCancerUrologic Oncology, and the British Journal of Urology International.

    Dr. Lotan was included in D Magazine's Best Doctors list for 2014, 2016, 20167, 2018, 2021, and 2022.

  • Education
    Medical School
    Baylor College of Medicine (1997)
    Internship
    UT Southwestern Medical Center (1998), General Surgery
    Residency
    UT Southwestern Medical Center (1999), General Surgery
    Residency
    UT Southwestern Medical Center (2003), Urology
  • Research Interest
    • Biomarker research
    • Decision analysis and outcomes research
    • Robotic and laparoscopic surgery
    • Urologic oncology
  • Publications

    Star Featured Publications

    Featured Featured Featured Featured Featured
    BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress
    Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y Urol Oncol May 2010 28(3): 334-7 334-7
    Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers
    Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C. Sagalowsky AI, Ashfaq R, Lotan Y J Urol May 2010 183(5) 1744-50
    The influence of body mass index on the cost of radical prostatectomy for prostate cancer
    Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, Lotan Y BJU Int March 2010 23
    Role of biomarkers to predict outcomes and response to therapy
    Lotan Y Urol Oncol January 2010 28(1) 97-101
    Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study
    Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Muller SC, Sagalowsky AI, Lotan Y Clin Cancer Res November 2009 15(22) 7012-19
  • Honors & Awards
    • Merit Award
      American Society of Clinical Oncology (ASCO) Cancer Foundation at the Genitourinary Cancers Symposium (2009)
    • Best Poster
      Society of Urologic Oncology Annual Meeting on Extraordinary Opportunities for Discovery National Cancer Institute (2008)
    • Who’s Who in America
      (2008)
    • Gerald P. Murphy Scholar Award
      Recognition of Research in Prostate Cancer (2003)
    • The Pfizer Scholars in Urology Award
      Urology Pathology Course (2002)
  • Professional Associations/Affiliations
    • American Association for Cancer Research
    • American Urologic Association
    • National Urologic Ultrasound Faculty
    • R.O.C.K. Society
    • Society of Urologic Oncology/Society of Endourology